Profound Medical (NASDAQ:PROF – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Profound Medical to related businesses based on the strength of its valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.
Profitability
This table compares Profound Medical and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -171.57% | -63.03% | -51.24% |
| Profound Medical Competitors | -278.24% | -150.08% | -21.87% |
Earnings & Valuation
This table compares Profound Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Profound Medical | $16.10 million | -$42.57 million | -7.36 |
| Profound Medical Competitors | $1.88 billion | $139.14 million | 9.47 |
Profound Medical’s competitors have higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Profound Medical has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Profound Medical’s competitors have a beta of 2.53, indicating that their average stock price is 153% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Profound Medical and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
| Profound Medical Competitors | 4274 | 10549 | 18323 | 829 | 2.46 |
Profound Medical currently has a consensus target price of $11.50, indicating a potential upside of 59.50%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.31%. Given Profound Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than its competitors.
Summary
Profound Medical competitors beat Profound Medical on 7 of the 13 factors compared.
Profound Medical Company Profile
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.
